The drug also reduced homeostasis model assessment of insulin resistance ( HOMA-IR ) index , systolic blood pressure , and diastolic blood pressure among participants with T2DM .
The changes in hemoglobin A1c ( HbA1c ) , low-density lipoprotein cholesterol , and high-density lipoprotein cholesterol were negligible .
Subgroup analysis comparing the resveratrol supplementation doses of < 100 mg/d versus ≥ 100 mg/d revealed a significant difference in fasting plasma glucose .
In particular , the latter dose presented more favorable results .
This meta- analysis provides evidence that supplementation of resveratrol may benefit management of T2DM
Although the regular consumption of resveratrol has been known to improve glucose homeostasis and reverse insulin resistance in type 2 diabetes mellitus ( T2DM ) , the reported results are inconsistent .
Thus , we aim ed to assess the effects of resveratrol on glycemic control and insulin sensitivity among patients with T2DM .
Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure.
OBJECTIVES The primary aims of the study were to examine the effect of resveratrol on skeletal muscle SIRT1 expression and energy expenditure in subjects with Type 2 diabetes mellitus ( T2DM ) . BACKGROUND Animal and in vivo studies indicate that resveratrol increases SIRT1 expression that stimulates PGC1α activity . Subsequent upregulation of AMPK and GLUT4 expression are associated with improved insulin sensitivity in peripheral tissues . METHODS Ten subjects with T2DM were r and omized in a double-blind fashion to receive 3 g resveratrol or placebo daily for 12 weeks . Secondary outcomes include measures of AMPK , p-AMPK and GLUT4 expression levels , energy expenditure , physical activity levels , distribution of abdominal adipose tissue and skeletal muscle fiber type composition , body weight , HbA1c , plasma lipid subfraction , adiponectin levels , and insulin sensitivity . RESULTS There was a significant increase in both SIRT1 expression ( 2.01 vs. 0.86 arbitrary units [ AU ] , p = .016 ) and p-AMPK to AMPK expression ratio ( 2.04 vs. 0.79 AU , p = .032 ) in the resveratrol group compared with the placebo group . Although the percentage of absolute change ( 8.6 vs. -13.9 % , p = .033 ) and percentage of predicted resting metabolic rate ( RMR ; 7.8 vs. -13.9 % , p = .013 ) were increased following resveratrol , there was a significant reduction in average daily activity ( -38 vs. 43.2 % , p = .028 ) and step counts ( -39.5 vs. 11.8 % , p = .047 ) when compared with placebo . CONCLUSIONS In patients with T2DM , treatment with resveratrol regulates energy expenditure through increased skeletal muscle SIRT1 and AMPK expression . These findings indicate that resveratrol may have beneficial exercise-mimetic effects in patients with T2DM
The drug also reduced homeostasis model assessment of insulin resistance ( HOMA-IR ) index , systolic blood pressure , and diastolic blood pressure among participants with T2DM .
The changes in hemoglobin A1c ( HbA1c ) , low-density lipoprotein cholesterol , and high-density lipoprotein cholesterol were negligible .
Subgroup analysis comparing the resveratrol supplementation doses of < 100 mg/d versus ≥ 100 mg/d revealed a significant difference in fasting plasma glucose .
In particular , the latter dose presented more favorable results .
This meta- analysis provides evidence that supplementation of resveratrol may benefit management of T2DM
Although the regular consumption of resveratrol has been known to improve glucose homeostasis and reverse insulin resistance in type 2 diabetes mellitus ( T2DM ) , the reported results are inconsistent .
Thus , we aim ed to assess the effects of resveratrol on glycemic control and insulin sensitivity among patients with T2DM .